There were 23 press releases posted in the last 24 hours and 166,036 in the last 365 days.

Global Multiple Sclerosis Therapeutics Industry

Multiple Sclerosis Therapeutics market worldwide is projected to grow by US$4 Billion, driven by a compounded growth of 2. 6%. Beta Interferon, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.

/EIN News/ -- New York, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Multiple Sclerosis Therapeutics Industry" - https://www.reportlinker.com/p05818011/?utm_source=GNW
7%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.8 Billion by the year 2025, Beta Interferon will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 2.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$151.7 Million to the region’s size and clout in the next 5 to 6 years. Over US$116.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Beta Interferon will reach a market size of US$162.3 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 4.2% over the next couple of years and add approximately US$1.1 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, AbbVie, Inc.; Bayer AG; Biogen, Inc.; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.


Read the full report: https://www.reportlinker.com/p05818011/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Multiple Sclerosis Therapeutics Competitor Market Share
Scenario Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: Multiple Sclerosis Therapeutics Global Market
Estimates and Forecasts in US$ Million by Region/Country:
2018-2025
Table 2: Multiple Sclerosis Therapeutics Global Retrospective
Market Scenario in US$ Million by Region/Country: 2009-2017
Table 3: Multiple Sclerosis Therapeutics Market Share Shift
across Key Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: Beta Interferon (Drug Class) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 5: Beta Interferon (Drug Class) Historic Market Analysis
by Region/Country in US$ Million: 2009 to 2017
Table 6: Beta Interferon (Drug Class) Market Share Breakdown of
Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
Table 7: Corticosteroids (Drug Class) Potential Growth Markets
Worldwide in US$ Million: 2018 to 2025
Table 8: Corticosteroids (Drug Class) Historic Market
Perspective by Region/Country in US$ Million: 2009 to 2017
Table 9: Corticosteroids (Drug Class) Market Sales Breakdown by
Region/Country in Percentage: 2009 VS 2019 VS 2025
Table 10: Monoclonal Antibodies (Drug Class) Geographic Market
Spread Worldwide in US$ Million: 2018 to 2025
Table 11: Monoclonal Antibodies (Drug Class) Region Wise
Breakdown of Global Historic Demand in US$ Million: 2009 to
2017
Table 12: Monoclonal Antibodies (Drug Class) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025
Table 13: Antineoplastic Agents (Drug Class) World Market
Estimates and Forecasts by Region/Country in US$ Million: 2018
to 2025
Table 14: Antineoplastic Agents (Drug Class) Market Historic
Review by Region/Country in US$ Million: 2009 to 2017
Table 15: Antineoplastic Agents (Drug Class) Market Share
Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Other Drug Class (Drug Class) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 17: Other Drug Class (Drug Class) Historic Market
Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Other Drug Class (Drug Class) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025
Table 19: Oral (Therapeutics) World Market Estimates and
Forecasts in US$ Million by Region/Country: 2018 to 2025
Table 20: Oral (Therapeutics) Market Worldwide Historic Review
by Region/Country in US$ Million: 2009 to 2017
Table 21: Oral (Therapeutics) Market Percentage Share
Distribution by Region/Country: 2009 VS 2019 VS 2025
Table 22: Injection (Therapeutics) Market Opportunity Analysis
Worldwide in US$ Million by Region/Country: 2018 to 2025
Table 23: Injection (Therapeutics) Global Historic Demand in
US$ Million by Region/Country: 2009 to 2017
Table 24: Injection (Therapeutics) Market Share Distribution in
Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Multiple Sclerosis Therapeutics Market Share (in %) by
Company: 2019 & 2025
Table 25: United States Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 26: Multiple Sclerosis Therapeutics Market in the United
States by Drug Class: A Historic Review in US$ Million for
2009-2017
Table 27: United States Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 28: United States Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 29: Multiple Sclerosis Therapeutics Market in the United
States by Therapeutics: A Historic Review in US$ Million for
2009-2017
Table 30: United States Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
CANADA
Table 31: Canadian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 32: Canadian Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 33: Multiple Sclerosis Therapeutics Market in Canada:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 34: Canadian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 35: Canadian Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 36: Multiple Sclerosis Therapeutics Market in Canada:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
JAPAN
Table 37: Japanese Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by Drug
Class for the Period 2018-2025
Table 38: Multiple Sclerosis Therapeutics Market in Japan:
Historic Sales Analysis in US$ Million by Drug Class for the
Period 2009-2017
Table 39: Japanese Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 40: Japanese Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by
Therapeutics for the Period 2018-2025
Table 41: Multiple Sclerosis Therapeutics Market in Japan:
Historic Sales Analysis in US$ Million by Therapeutics for the
Period 2009-2017
Table 42: Japanese Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
CHINA
Table 43: Chinese Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Drug Class for the Period 2018-2025
Table 44: Multiple Sclerosis Therapeutics Historic Market
Analysis in China in US$ Million by Drug Class: 2009-2017
Table 45: Chinese Multiple Sclerosis Therapeutics Market by
Drug Class: Percentage Breakdown of Sales for 2009, 2019, and
2025
Table 46: Chinese Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 47: Multiple Sclerosis Therapeutics Historic Market
Analysis in China in US$ Million by Therapeutics: 2009-2017
Table 48: Chinese Multiple Sclerosis Therapeutics Market by
Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and
2025
EUROPE
Market Facts & Figures
European Multiple Sclerosis Therapeutics Market: Competitor
Market Share Scenario (in %) for 2019 & 2025
Table 49: European Multiple Sclerosis Therapeutics Market
Demand Scenario in US$ Million by Region/Country: 2018-2025
Table 50: Multiple Sclerosis Therapeutics Market in Europe: A
Historic Market Perspective in US$ Million by Region/Country
for the Period 2009-2017
Table 51: European Multiple Sclerosis Therapeutics Market Share
Shift by Region/Country: 2009 VS 2019 VS 2025
Table 52: European Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 53: Multiple Sclerosis Therapeutics Market in Europe in
US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 54: European Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 55: European Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 56: Multiple Sclerosis Therapeutics Market in Europe in
US$ Million by Therapeutics: A Historic Review for the Period
2009-2017
Table 57: European Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
FRANCE
Table 58: Multiple Sclerosis Therapeutics Market in France by
Drug Class: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 59: French Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Drug Class: 2009-2017
Table 60: French Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 61: Multiple Sclerosis Therapeutics Market in France by
Therapeutics: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 62: French Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Therapeutics: 2009-2017
Table 63: French Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
GERMANY
Table 64: Multiple Sclerosis Therapeutics Market in Germany:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 65: German Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 66: German Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 67: Multiple Sclerosis Therapeutics Market in Germany:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 68: German Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 69: German Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
ITALY
Table 70: Italian Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Drug Class for the Period 2018-2025
Table 71: Multiple Sclerosis Therapeutics Historic Market
Analysis in Italy in US$ Million by Drug Class: 2009-2017
Table 72: Italian Multiple Sclerosis Therapeutics Market by
Drug Class: Percentage Breakdown of Sales for 2009, 2019, and
2025
Table 73: Italian Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 74: Multiple Sclerosis Therapeutics Historic Market
Analysis in Italy in US$ Million by Therapeutics: 2009-2017
Table 75: Italian Multiple Sclerosis Therapeutics Market by
Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and
2025
UNITED KINGDOM
Table 76: United Kingdom Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Drug Class for the Period 2018-2025
Table 77: Multiple Sclerosis Therapeutics Market in the United
Kingdom: Historic Sales Analysis in US$ Million by Drug Class
for the Period 2009-2017
Table 78: United Kingdom Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 79: United Kingdom Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Therapeutics for the Period 2018-2025
Table 80: Multiple Sclerosis Therapeutics Market in the United
Kingdom: Historic Sales Analysis in US$ Million by Therapeutics
for the Period 2009-2017
Table 81: United Kingdom Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
SPAIN
Table 82: Spanish Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 83: Spanish Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 84: Multiple Sclerosis Therapeutics Market in Spain:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 85: Spanish Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 86: Spanish Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 87: Multiple Sclerosis Therapeutics Market in Spain:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
RUSSIA
Table 88: Russian Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 89: Multiple Sclerosis Therapeutics Market in Russia by
Drug Class: A Historic Review in US$ Million for 2009-2017
Table 90: Russian Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 91: Russian Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 92: Multiple Sclerosis Therapeutics Market in Russia by
Therapeutics: A Historic Review in US$ Million for 2009-2017
Table 93: Russian Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 94: Rest of Europe Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 95: Multiple Sclerosis Therapeutics Market in Rest of
Europe in US$ Million by Drug Class: A Historic Review for the
Period 2009-2017
Table 96: Rest of Europe Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 97: Rest of Europe Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 98: Multiple Sclerosis Therapeutics Market in Rest of
Europe in US$ Million by Therapeutics: A Historic Review for
the Period 2009-2017
Table 99: Rest of Europe Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 100: Asia-Pacific Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Region/Country:
2018-2025
Table 101: Multiple Sclerosis Therapeutics Market in
Asia-Pacific: Historic Market Analysis in US$ Million by
Region/Country for the Period 2009-2017
Table 102: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 103: Multiple Sclerosis Therapeutics Market in
Asia-Pacific by Drug Class: Estimates and Projections in US$
Million for the Period 2018-2025
Table 104: Asia-Pacific Multiple Sclerosis Therapeutics
Historic Market Scenario in US$ Million by Drug Class:
2009-2017
Table 105: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 106: Multiple Sclerosis Therapeutics Market in
Asia-Pacific by Therapeutics: Estimates and Projections in US$
Million for the Period 2018-2025
Table 107: Asia-Pacific Multiple Sclerosis Therapeutics
Historic Market Scenario in US$ Million by Therapeutics:
2009-2017
Table 108: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
AUSTRALIA
Table 109: Multiple Sclerosis Therapeutics Market in Australia:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 110: Australian Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 111: Australian Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 112: Multiple Sclerosis Therapeutics Market in Australia:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 113: Australian Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 114: Australian Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
INDIA
Table 115: Indian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 116: Indian Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 117: Multiple Sclerosis Therapeutics Market in India:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 118: Indian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 119: Indian Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 120: Multiple Sclerosis Therapeutics Market in India:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
SOUTH KOREA
Table 121: Multiple Sclerosis Therapeutics Market in South
Korea: Recent Past, Current and Future Analysis in US$ Million
by Drug Class for the Period 2018-2025
Table 122: South Korean Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 123: Multiple Sclerosis Therapeutics Market Share
Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025
Table 124: Multiple Sclerosis Therapeutics Market in South
Korea: Recent Past, Current and Future Analysis in US$ Million
by Therapeutics for the Period 2018-2025
Table 125: South Korean Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 126: Multiple Sclerosis Therapeutics Market Share
Distribution in South Korea by Therapeutics: 2009 VS 2019 VS
2025
REST OF ASIA-PACIFIC
Table 127: Rest of Asia-Pacific Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Drug Class for the Period 2018-2025
Table 128: Multiple Sclerosis Therapeutics Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Million by Drug
Class for the Period 2009-2017
Table 129: Rest of Asia-Pacific Multiple Sclerosis Therapeutics
Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 130: Rest of Asia-Pacific Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Therapeutics for the Period 2018-2025
Table 131: Multiple Sclerosis Therapeutics Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Million by
Therapeutics for the Period 2009-2017
Table 132: Rest of Asia-Pacific Multiple Sclerosis Therapeutics
Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 133: Latin American Multiple Sclerosis Therapeutics
Market Trends by Region/Country in US$ Million: 2018-2025
Table 134: Multiple Sclerosis Therapeutics Market in Latin
America in US$ Million by Region/Country: A Historic
Perspective for the Period 2009-2017
Table 135: Latin American Multiple Sclerosis Therapeutics
Market Percentage Breakdown of Sales by Region/Country: 2009,
2019, and 2025
Table 136: Latin American Multiple Sclerosis Therapeutics
Market Growth Prospects in US$ Million by Drug Class for the
Period 2018-2025
Table 137: Multiple Sclerosis Therapeutics Historic Market
Analysis in Latin America in US$ Million by Drug Class:
2009-2017
Table 138: Latin American Multiple Sclerosis Therapeutics
Market by Drug Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
Table 139: Latin American Multiple Sclerosis Therapeutics
Market Growth Prospects in US$ Million by Therapeutics for the
Period 2018-2025
Table 140: Multiple Sclerosis Therapeutics Historic Market
Analysis in Latin America in US$ Million by Therapeutics:
2009-2017
Table 141: Latin American Multiple Sclerosis Therapeutics
Market by Therapeutics: Percentage Breakdown of Sales for
2009, 2019, and 2025
ARGENTINA
Table 142: Argentinean Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 143: Multiple Sclerosis Therapeutics Market in Argentina
in US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 144: Argentinean Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 145: Argentinean Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 146: Multiple Sclerosis Therapeutics Market in Argentina
in US$ Million by Therapeutics: A Historic Review for the
Period 2009-2017
Table 147: Argentinean Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
BRAZIL
Table 148: Multiple Sclerosis Therapeutics Market in Brazil by
Drug Class: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 149: Brazilian Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Drug Class: 2009-2017
Table 150: Brazilian Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 151: Multiple Sclerosis Therapeutics Market in Brazil by
Therapeutics: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 152: Brazilian Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Therapeutics: 2009-2017
Table 153: Brazilian Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
MEXICO
Table 154: Multiple Sclerosis Therapeutics Market in Mexico:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 155: Mexican Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 156: Mexican Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 157: Multiple Sclerosis Therapeutics Market in Mexico:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 158: Mexican Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 159: Mexican Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 160: Rest of Latin America Multiple Sclerosis
Therapeutics Market Estimates and Projections in US$ Million by
Drug Class: 2018 to 2025
Table 161: Multiple Sclerosis Therapeutics Market in Rest of
Latin America by Drug Class: A Historic Review in US$ Million
for 2009-2017
Table 162: Rest of Latin America Multiple Sclerosis
Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019
VS 2025
Table 163: Rest of Latin America Multiple Sclerosis
Therapeutics Market Estimates and Projections in US$ Million by
Therapeutics: 2018 to 2025
Table 164: Multiple Sclerosis Therapeutics Market in Rest of
Latin America by Therapeutics: A Historic Review in US$ Million
for 2009-2017
Table 165: Rest of Latin America Multiple Sclerosis
Therapeutics Market Share Breakdown by Therapeutics: 2009 VS
2019 VS 2025
MIDDLE EAST
Table 166: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by
Region/Country: 2018-2025
Table 167: Multiple Sclerosis Therapeutics Market in the Middle
East by Region/Country in US$ Million: 2009-2017
Table 168: The Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Region/Country: 2009, 2019, and 2025
Table 169: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by Drug Class:
2018 to 2025
Table 170: The Middle East Multiple Sclerosis Therapeutics
Historic Market by Drug Class in US$ Million: 2009-2017
Table 171: Multiple Sclerosis Therapeutics Market in the Middle
East: Percentage Share Breakdown of Sales by Drug Class for
2009, 2019, and 2025
Table 172: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by Therapeutics:
2018 to 2025
Table 173: The Middle East Multiple Sclerosis Therapeutics
Historic Market by Therapeutics in US$ Million: 2009-2017
Table 174: Multiple Sclerosis Therapeutics Market in the Middle
East: Percentage Share Breakdown of Sales by Therapeutics for
2009, 2019, and 2025
IRAN
Table 175: Iranian Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by Drug
Class for the Period 2018-2025
Table 176: Multiple Sclerosis Therapeutics Market in Iran:
Historic Sales Analysis in US$ Million by Drug Class for the
Period 2009-2017
Table 177: Iranian Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 178: Iranian Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by
Therapeutics for the Period 2018-2025
Table 179: Multiple Sclerosis Therapeutics Market in Iran:
Historic Sales Analysis in US$ Million by Therapeutics for the
Period 2009-2017
Table 180: Iranian Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
ISRAEL
Table 181: Israeli Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 182: Multiple Sclerosis Therapeutics Market in Israel in
US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 183: Israeli Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 184: Israeli Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 185: Multiple Sclerosis Therapeutics Market in Israel in
US$ Million by Therapeutics: A Historic Review for the Period
2009-2017
Table 186: Israeli Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 187: Saudi Arabian Multiple Sclerosis Therapeutics Market
Growth Prospects in US$ Million by Drug Class for the Period
2018-2025
Table 188: Multiple Sclerosis Therapeutics Historic Market
Analysis in Saudi Arabia in US$ Million by Drug Class:
2009-2017
Table 189: Saudi Arabian Multiple Sclerosis Therapeutics Market
by Drug Class: Percentage Breakdown of Sales for 2009, 2019,
and 2025
Table 190: Saudi Arabian Multiple Sclerosis Therapeutics Market
Growth Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 191: Multiple Sclerosis Therapeutics Historic Market
Analysis in Saudi Arabia in US$ Million by Therapeutics:
2009-2017
Table 192: Saudi Arabian Multiple Sclerosis Therapeutics Market
by Therapeutics: Percentage Breakdown of Sales for 2009, 2019,
and 2025
UNITED ARAB EMIRATES
Table 193: Multiple Sclerosis Therapeutics Market in the United
Arab Emirates: Recent Past, Current and Future Analysis in US$
Million by Drug Class for the Period 2018-2025
Table 194: United Arab Emirates Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 195: Multiple Sclerosis Therapeutics Market Share
Distribution in United Arab Emirates by Drug Class: 2009 VS
2019 VS 2025
Table 196: Multiple Sclerosis Therapeutics Market in the United
Arab Emirates: Recent Past, Current and Future Analysis in US$
Million by Therapeutics for the Period 2018-2025
Table 197: United Arab Emirates Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 198: Multiple Sclerosis Therapeutics Market Share
Distribution in United Arab Emirates by Therapeutics: 2009 VS
2019 VS 2025
REST OF MIDDLE EAST
Table 199: Multiple Sclerosis Therapeutics Market in Rest of
Middle East: Recent Past, Current and Future Analysis in US$
Million by Drug Class for the Period 2018-2025
Table 200: Rest of Middle East Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 201: Rest of Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 202: Multiple Sclerosis Therapeutics Market in Rest of
Middle East: Recent Past, Current and Future Analysis in US$
Million by Therapeutics for the Period 2018-2025
Table 203: Rest of Middle East Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 204: Rest of Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
AFRICA
Table 205: African Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 206: Multiple Sclerosis Therapeutics Market in Africa by
Drug Class: A Historic Review in US$ Million for 2009-2017
Table 207: African Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 208: African Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 209: Multiple Sclerosis Therapeutics Market in Africa by
Therapeutics: A Historic Review in US$ Million for 2009-2017
Table 210: African Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBVIE
BAYER AG
BIOGEN
MERCK & CO., INC.
NOVARTIS INTERNATIONAL AG
PFIZER
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05818011/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
Distribution channels: Media, Advertising & PR


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.